WEKO3
アイテム
認知症診断・層別化バイオマーカーとしての血液中タウ分子種：実臨床への応用にむけて
https://repo.qst.go.jp/records/84385
https://repo.qst.go.jp/records/843857ce2c53f-14c3-4e9d-adac-054e37f3cab6
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-12-24 | |||||
| タイトル | ||||||
| タイトル | 認知症診断・層別化バイオマーカーとしての血液中タウ分子種：実臨床への応用にむけて | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
徳田, 隆彦
× 徳田, 隆彦× Takahiko, Tokuda |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | 演題名: 認知症診断・層別化バイオマーカーとしての血液中タウ分子種：実臨床への応用にむけて Title: Tau species in human biological fluids as the diagnostic and stratification biomarkers for dementia: considerations for the clinical application There is still a substantial unmet need for less invasive and lower-cost molecular biomarkers, namely blood-based biomarkers, for the diagnosis and stratification of patients with dementia including Alzheimer's disease (AD). We developed the world's first immunoassay to quantify plasma tau phosphorylated at threonine 181 (p-tau181) in 2017 by using an ultrasensitive digital array technology (Simoa system, Quanterix, USA). With this original assay, we reported that the plasma levels of p-tau181 were significantly higher in AD patients than those in the controls. Our study suggested that plasma p-tau181 is a promising blood biomarker for brain AD pathology. After our study, substantial evidence of the usefulness of plasma p-tau assays in the diagnosis of AD has been accumulating internationally. Now, we are developing other blood biomarkers for AD and other dementias, such as p-tau species other than p-tau181 as well as Aβ40/42, neurofilament light (NfL), TDP-43 and α-synuclein. Furthermore, for the validation and future use of those biomarkers in the clinical settings, it is essential that we should collect large-scale blood samples obtained from patients with a highly reliable diagnosis of underlying diseases. Such a "reliable diagnosis" used to mean the pathological diagnosis of the patients, but now neuroimaging techniques, such as PET imaging, of pathognomonic accumulation of abnormal protein aggregates can be used as a substitute for the pathological diagnosis. From this recognition, we have just launched the Multicenter Alliance for Brain Biomarkers (MABB) in August 2020 and have started to enroll patients with cognitive impairment and controls to collect both PET imaging data and blood samples. In my talk, I will present our results and recent studies reported from other groups regarding tau species and other dementia-related molecules in human blood as the candidates of blood-based biomarkers for AD and neurodegenerative dementias. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 日本神経化学会大会(第64回) | |||||
| 発表年月日 | ||||||
| 日付 | 2021-10-01 | |||||
| 日付タイプ | Issued | |||||
